2 enrolling by invitation. 2 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Enrolling by invitation 2 |
| Phase 1 | 1 | Enrolling by invitation 1 |
| Phase 3 | 1 | Enrolling by invitation 1 |
Follow Nervous System Neoplasms: new trials by email Literature Review of Nervous System Neoplasms trials Research Report on Nervous System Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA BNCT, ［18F］FBPA - Thoracic Solid Malignant Tumor | Phase 1 / Phase 2 | Enrolling by invitation | Stella Pharma Corporation | 30 | 2025-04-10 | 2025-11-19 |
| Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis Efgartigimod IV or Efgartigimod PH20 SC - Generalized Myasthenia Gravis, gMG | Phase 2 / Phase 3 | Enrolling by invitation | argenx | 12 | 2022-08-18 | 2026-04-23 |
Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Esophageal Neoplasms (1) · Mesothelioma, Malignant (1) · Myasthenia Gravis (1) · Neurofibrosarcoma (1)
Neoplasms (2) · Neoplasms by Site (2) · Nervous System Diseases (2) · Neuromuscular Diseases (2) · Adenoma (1) · Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Breast Diseases (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Esophageal Diseases (1) · Fibrosarcoma (1)
Stella Pharma Corporation (1) · argenx (1)
Belgium (1) · Canada (1) · France (1) · Germany (1) · Israel (1) · Japan (1) · Netherlands (1) · Poland (1) · Spain (1) · United Kingdom (1) · United States (1)
2023 (1)